Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/ajh.27060 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of anlotinib combined with vinorelbine as second‑line treatment for elderly patients with advanced squamous cell lung carcinoma: A retrospective cohort.
Mol Clin Oncol
February 2025
Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430079, P.R. China.
The aim of the present study was to investigate the efficacy and safety of anlotinib combined with vinorelbine (NVB) as a second-line treatment for elderly patients with advanced squamous cell lung carcinoma (SqCLC). The present retrospective analysis included 48 elderly patients (aged ≥65 years) diagnosed with advanced SqCLC who received anlotinib in combination with NVB as a second-line therapy between January 2021 and December 2023. The primary endpoints assessed were overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR) and safety profile.
View Article and Find Full Text PDFSymptom management in isocitrate dehydrogenase mutant glioma.
Neurooncol Pract
February 2025
Department of Neurology, Leiden University Medical Center, Leiden, The Netherlands.
According to the 2021 World Health Organization classification of CNS tumors, gliomas harboring a mutation in isocitrate dehydrogenase (mIDH) are considered a distinct disease entity, typically presenting in adult patients before the age of 50 years. Given their multiyear survival, patients with mIDH glioma are affected by tumor and treatment-related symptoms that can have a large impact on the daily life of both patients and their caregivers for an extended period of time. Selective oral inhibitors of mIDH enzymes have recently joined existing anticancer treatments, including resection, radiotherapy, and chemotherapy, as an additional targeted treatment modality.
View Article and Find Full Text PDFAnaesthetic management of oncological disease in pregnancy: a narrative review.
Anaesthesia
January 2025
Department of Anaesthesia, University Hospital of Wales, Cardiff, UK.
Introduction: Cancer complicates approximately 1 in 2000 pregnancies, with increasing incidence due to factors such as increased maternal age, obesity and advancements in antenatal testing. Anaesthetists play a crucial role in managing pregnant patients with cancer, both during delivery and in providing anaesthesia for oncological treatments. This review explores the challenges in anaesthetic management and specific considerations for common cancers encountered in pregnant patients.
View Article and Find Full Text PDFIntensity-modulated radiation therapy for early-stage breast cancer: a systematic review and meta-analysis.
Sao Paulo Med J
January 2025
Professor, Discipline of Evidence-Based Medicine, Escola Paulista de Medicina (EPM), Universidade Federal de São Paulo (Unifesp), São Paulo, SP, Brazil; Consultant, Centre of Health Technology Assessment, Hospital Sírio-Libanês, São Paulo (SP), Brazil.
Background: Radiation therapy (RT) is a standard treatment for non-metastatic breast cancer and is associated with acute and late toxicities. Intensity-modulated RT (IMRT) may decrease toxicity and is convenient for patients.
Objectives: To assess the efficacy and safety of IMRT in women with early stage breast cancer.
Purpose: The aim of this study was to evaluate the efficacy and safety of 177Lu-DOTA-IBA for pain palliation in participants with bone metastases and confirm its potential for treating bone metastasis.
Patients And Methods: Overall, 69 participants with bone metastases were included. 68Ga-DOTA-IBA PET/CT was performed within 1 week before treatment.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!